0 8

Cited 0 times in

Histone deacetylase 6 inhibitor tubastatin A attenuates angiotensin II-induced hypertension by preventing cystathionine gamma-lyase protein degradation

Chi, Z; Byeon, HE; Seo, E; Nguyen, QT; Lee, W; Jeong, Y; Choi, J; Pandey, D; Berkowitz, DE; Kim, JH; Lee, SY
Pharmacological research, 146. : 104281-104281, 2019
Journal Title
Pharmacological research
Cystathionine gamma-lyase (CSEgamma) is a hydrogen sulfide (H2S)-producing enzyme. Endothelial H2S production can mediate vasodilatory effects, contributing to the alleviation of hypertension (high blood pressure). Recent studies have suggested a role of histone deacetylase 6 (HDAC6) in hypertension, although its underlying mechanisms are poorly understood. Here, we addressed the potential regulation of CSEgamma by HDAC6 in angiotensin II (AngII)-induced hypertension and its molecular details focusing on CSEgamma posttranslational modification. Treatment of mice with a selective HDAC6 inhibitor tubastatin A (TubA) alleviated high blood pressure and vasoconstriction induced by AngII. Cotreatment of the aorta and human aortic endothelial cells with TubA recovered AngII-mediated decreased H2S levels. AngII treatment upregulated HDAC6 mRNA and protein expression, but conversely downregulated CSEgamma protein. Notably, potent HDAC6 inhibitors and HDAC6 siRNA as well as a proteasomal inhibitor increased CSEgamma protein levels and blocked the downregulatory effect of AngII on CSEgamma. In contrast, other HDAC isoforms-specific inhibitors and siRNAs did not show such blocking effects. Transfected CSEgamma protein levels were also reciprocally regulated by AngII and TubA, and were reduced by wild-type, but not by deacetylase-deficient, HDAC6. Moreover, TubA significantly increased both protein stability and K73 acetylation level of CSEgamma. Consistent with these results, AngII induced CSEgamma ubiquitination and degradation, which was inhibited by TubA. Our results indicate that AngII promoted HDAC6-dependent deacetylation of CSEgamma at K73 residue, leading to its ubiquitin-mediated proteolysis, which underlies AngII-induced hypertension. Overall, this study suggests that upregulation of CSEgamma and H2S through HDAC6 inhibition may be considered as a valid strategy for preventing the progression of hypertension.
Angiotensin IIAngiotensin II (PubChem CID: 172198)Cystathionine γ-lyaseHistone deacetylase 6Hydrogen sulfideHypertensionTubastatin ATubastatin A (PubChem CID: 49850262)
MeSH terms
Angiotensin II / pharmacology*AnimalsAorta / cytologyCystathionine gamma-Lyase / metabolism*Endothelial Cells / metabolismHEK293 CellsHistone Deacetylase 6 / antagonists & inhibitors*Histone Deacetylase 6 / geneticsHistone Deacetylase 6 / metabolismHistone Deacetylase Inhibitors / pharmacology*HumansHydrogen Sulfide / metabolism*Hydroxamic Acids / pharmacology*Hypertension / chemically inducedHypertension / geneticsHypertension / metabolism*Indoles / pharmacology*MaleMice, Inbred C57BLProteolysis / drug effects
Appears in Collections:
Journal Papers > Research Organization > Institute for Medical Sciences
AJOU Authors
변, 혜은이, 상윤
Files in This Item:
RIS (EndNote)
XLS (Excel)


해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.